Praxis Precision Medicines to Participate in September Investor Conferences
PRAX(NASDAQ:PRAX) BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis’ management will be attending and presenting in three upcoming investor conferences:
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX(NASDAQ:PRAX) BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on September 2, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 6,238 shares of its common stock to eight new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
PRAX(NASDAQ:PRAX) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
PRAX(NASDAQ:PRAX) BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36th International Epilepsy Consortium (IEC).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
PRAXNEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating cl ims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
PRAXBOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming International Epilepsy Congress (IEC), taking place August 30–September 3, 2025, in Lisbon, Portugal.
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
PRAXLOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or "the Company") (NASDAQ: PRAX) for violations of the securities...
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
PRAXLOS ANGELES--(BUSINESS WIRE)---- $PRAX--PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
PRAXNEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
PRAXNEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAXBOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on August 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,875 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Needham Reiterates Buy on Praxis Precision Medicine, Maintains $80 Price Target
PRAXOppenheimer Assumes Praxis Precision Medicine at Outperform, Announces Price Target of $97
PRAXPraxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
PRAXChardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
PRAXChardan Capital Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $80
PRAXWedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $28
PRAXPraxis Precision Medicines Highlights Developmental And Epileptic Encephalopathies Clinical Program Updates At Virtual Investor Event
PRAXNeedham Reiterates Buy on Praxis Precision Medicine, Maintains $80 Price Target
PRAXPraxis Precision Medicine Q1 EPS $(3.29) Misses $(3.17) Estimate
PRAXAssessing Praxis Precision Medicine: Insights From 8 Financial Analysts
PRAXHC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target
PRAXDeep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)
PRAXNeedham Reiterates Buy on Praxis Precision Medicine, Maintains $85 Price Target
PRAXAnalysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
PRAXPraxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $85
PRAXBaird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $73
PRAXNeedham Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $85
PRAXAssessing Praxis Precision Medicine: Insights From 5 Financial Analysts
PRAXHC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $105
PRAXTrading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
PRAXPraxis Precision Medicines Provides Update On Interim Analysis For Study 1 Of Essential3 Program; Independent Data Monitoring Committee Recommended Study Be Stopped For Futility Due To Results Being Unlikely To Meet Endpoint
PRAXTrading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
PRAXReported Earlier, Praxis Announces 2025 Milestones: Advancing Relutrigine, Ulixacaltamide, And Rare Disease Programs With $470M In Cash Reserves
PRAXPraxis Precision Medicines Files Base Prospectus And $250M Sales Agreement Prospectus Supplement For Issuance Of Common Stock, Preferred Stock, Debt Securities, Warrants, And Units
PRAXPraxis Precision Medicine Q3 2024 GAAP EPS $(2.75) Misses $(1.99) Estimate, Sales $302.000K Beat $296.000K Estimate
PRAXOppenheimer Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $163
PRAXCritical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
PRAXTruist Securities Maintains Buy on Praxis Precision Medicine, Maintains $150 Price Target
PRAX